Promising First-In-Human Phase 1B Clinical Study Data from VRON-0200, a Novel, First-in-Class Checkpoint Modifier Immunotherapy for Chronic Hepatitis B Virus Functional Cure, Presented as ...
Ocean Biomedical, Inc. (OCEA)
Company Research
Source: Yahoo! Finance
VRON-0200 was well tolerated, with no serious adverse events (SAEs) observed: no patients discontinued treatment one treatment related adverse event was reported (flu-like symptoms which resolved without treatment) No other clinically relevant abnormalities in laboratory tests, including liver function tests, electrocardiograms (ECG), or vital signs were reported Immunologic assessments are ongoing, data expected to be submitted to an upcoming meeting March 27, 2024 /PRNewswire/ -- Virion Therapeutics, LLC, a clinical-stage biotechnology company, developing novel T cell-based immunotherapies , today announced promising safety results from the first-ever human data from its novel, first-in-class, checkpoint modifier immunotherapy, VRON-0200, for HBV functional cure, presented by Professor Grace Wong , M.D., from the Chinese University of Hong Kong , as a late breaker oral presentation at the rd Annual Meeting of APASL (The Asian Pacific Association for the Study of the Liver
Show less
Read more
Impact Snapshot
Event Time:
OCEA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCEA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCEA alerts
High impacting Ocean Biomedical, Inc. news events
Weekly update
A roundup of the hottest topics
OCEA
News
- Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-KGlobeNewswire
- Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASLGlobeNewswire
- Ocean Biomedical: Shooting Upward, But Not Somewhere I Want To Be (Rating Upgrade) [Seeking Alpha]Seeking Alpha
- Ocean Biomedical (NASDAQ: OCEA) Announces Joint Venture Partner, Virion Therapeutics to Present Their First Clinical Study Data as an Accepted Late Breaker Presentation at 2024 APASL Global Liver Meeting [Yahoo! Finance]Yahoo! Finance
- Ocean Biomedical (NASDAQ: OCEA) Announces Joint Venture Partner, Virion Therapeutics to Present Their First Clinical Study Data as an Accepted Late Breaker Presentation at 2024 APASL Global Liver MeetingGlobeNewswire
OCEA
Sec Filings
- 4/24/24 - Form 8-K
- 4/15/24 - Form 10-Q
- 4/15/24 - Form 10-Q/A
- OCEA's page on the SEC website